Leqembi Phase II Missed Clinical Endpoint But Still Provided Support For Amyloid Surrogate

 
• By Sue Sutter
Drug Review Profile: Leqembi
The primary clinical efficay endpoint's failure to hit its prespecified mark was no hurdle to accelerated approval. • Source: Pink Sheet/Shutterstock

More from Drug Review Profiles

More from Product Reviews